OBJECTIVE: To examine whether there were differential rates of hepatitis C virus (HCV) incidence in injecting drug-using youths who did and did not report involvement in survival sex work. DESIGN: Data were derived from 2 prospective cohort studies of injecting drug users (May 1, 1996, to July 31, 2007). Analyses were restricted to HCV antibody-negative youths who completed baseline and at least 1 follow-up assessment. SETTING: Vancouver, British Columbia, Canada. PARTICIPANTS: Of 3074 injecting drug users, 364 (11.8%) were youths (aged 14-24 years) with a median age of 21.3 years and a duration of injecting drug use of 3 years. Main Exposure Survival sex work involvement. MAIN OUTCOME MEASURE: The Kaplan-Meier method and Cox proportional hazards regression were used to compare HCV incidence among youths who did and did not report survival sex work. RESULTS: Baseline HCV prevalence was 51%, with youths involved in survival sex work significantly more likely to be HCV antibody positive (60% vs 44%; P = .002). In baseline HCV antibody-negative youths, the cumulative HCV incidence at 36 months was significantly higher in those involved in survival sex work (68.4% vs 38.8%; P < .001). The HCV incidence density was 36.8 (95% confidence interval [CI], 24.2-53.5) per 100 person-years in youths reporting survival sex work involvement at baseline compared with 14.1 (9.4-20.3) per 100 person-years in youths not reporting survival sex work. In multivariate Cox proportional hazards analyses, survival sex work was the strongest predictor of elevated HCV incidence (adjusted relative hazard, 2.30; 95% CI, 1.27-4.15). CONCLUSION: This study calls attention to the critical need for evidence-based social and structural HCV prevention efforts that target youths engaged in survival sex work.
OBJECTIVE: To examine whether there were differential rates of hepatitis C virus (HCV) incidence in injecting drug-using youths who did and did not report involvement in survival sex work. DESIGN: Data were derived from 2 prospective cohort studies of injecting drug users (May 1, 1996, to July 31, 2007). Analyses were restricted to HCV antibody-negative youths who completed baseline and at least 1 follow-up assessment. SETTING: Vancouver, British Columbia, Canada. PARTICIPANTS: Of 3074 injecting drug users, 364 (11.8%) were youths (aged 14-24 years) with a median age of 21.3 years and a duration of injecting drug use of 3 years. Main Exposure Survival sex work involvement. MAIN OUTCOME MEASURE: The Kaplan-Meier method and Cox proportional hazards regression were used to compare HCV incidence among youths who did and did not report survival sex work. RESULTS: Baseline HCV prevalence was 51%, with youths involved in survival sex work significantly more likely to be HCV antibody positive (60% vs 44%; P = .002). In baseline HCV antibody-negative youths, the cumulative HCV incidence at 36 months was significantly higher in those involved in survival sex work (68.4% vs 38.8%; P < .001). The HCV incidence density was 36.8 (95% confidence interval [CI], 24.2-53.5) per 100 person-years in youths reporting survival sex work involvement at baseline compared with 14.1 (9.4-20.3) per 100 person-years in youths not reporting survival sex work. In multivariate Cox proportional hazards analyses, survival sex work was the strongest predictor of elevated HCV incidence (adjusted relative hazard, 2.30; 95% CI, 1.27-4.15). CONCLUSION: This study calls attention to the critical need for evidence-based social and structural HCV prevention efforts that target youths engaged in survival sex work.
Authors: Steffanie A Strathdee; Morgan M Philbin; Shirley J Semple; Minya Pu; Prisci Orozovich; Gustavo Martinez; Remedios Lozada; Miguel Fraga; Adela de la Torre; Hugo Staines; Carlos Magis-Rodríguez; Thomas L Patterson Journal: Drug Alcohol Depend Date: 2007-08-21 Impact factor: 4.492
Authors: Cari L Miller; Caitlin Johnston; Patricia M Spittal; Kathy Li; Nancy Laliberté; Julio S G Montaner; Martin T Schechter Journal: Hepatology Date: 2002-09 Impact factor: 17.425
Authors: Shira M Goldenberg; Gudelia Rangel; Alicia Vera; Thomas L Patterson; Daniela Abramovitz; Jay G Silverman; Anita Raj; Steffanie A Strathdee Journal: AIDS Behav Date: 2012-05
Authors: Brittany Barker; Scott E Hadland; Huiru Dong; Kate Shannon; Thomas Kerr; Kora DeBeck Journal: J Public Health (Oxf) Date: 2019-06-01 Impact factor: 2.341
Authors: Shira M Goldenberg; Jill Chettiar; Paul Nguyen; Sabina Dobrer; Julio Montaner; Kate Shannon Journal: J Urban Health Date: 2014-08 Impact factor: 3.671
Authors: M Eugenia Socías; Kate Shannon; Julio S Montaner; Silvia Guillemi; Sabina Dobrer; Paul Nguyen; Shira Goldenberg; Kathleen Deering Journal: Can J Gastroenterol Hepatol Date: 2015-10-22
Authors: Camila Malta Romano; Isabel M V Guedes de Carvalho-Mello; Leda F Jamal; Fernando Lucas de Melo; Atila Iamarino; Marco Motoki; João Renato Rebello Pinho; Edward C Holmes; Paolo Marinho de Andrade Zanotto Journal: PLoS One Date: 2010-06-23 Impact factor: 3.240